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Abstract
Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments
for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in the psychiatric community
regarding its mathematical properties.
All 30 items range from 1 to 7 leading to a minimum total score of 30, implying that the PANSS is an interval
scale. For such interval scales straightforward calculation of relative changes is not appropriate. To calculate
outcome criteria based on a percent change as, e.g., the widely accepted response criterion, the scale has to be
transformed into a ratio scale beforehand. Recent publications have already pointed out the pitfall that ignoring
the scale level (interval vs. ratio scale) leads to a set of mathematical problems, potentially resulting in erroneous
results concerning the efficacy of the treatment.
Methods: A Pubmed search based on the PRISMA statement of the highest-ranked psychiatric journals (search
terms “PANSS” and “response”) was carried out. All articles containing percent changes were included and methods
of percent change calculation were analysed.
Results: This systematic literature research shows that the majority of authors (62%) actually appear to use
incorrect calculations. In most instances the method of calculation was not described in the manuscript.
Conclusions: These alarming results underline the need for standardized procedures for PANSS calculations.
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Background
The PANSS is currently the most established scale in
patients with schizophrenia. For example in the high
impact journal “Schizophrenia Bulletin” Kay’sp u b l i c a -
tion on the Positive and Negative Syndrome Scale
(PANSS) for Schizophrenia is the most frequently cited
article with more than 4000 citations (pubmed 05/2011)
[1]. Despite its common use there still seems to be pro-
found uncertainty within the psychiatric community
regarding its mathematical properties. The pitfall relates
to the calculation of proportions (including percent
changes), which are used in common outcome criteria
like response.
Dichotomized measures such as response can be
understood more intuitively than mean values and are
specifically endorsed by the European Medicines Agency
http://www.ema.europa.eu/htms/human/ich/ichefficacy.
htm.
As pointed out in a previous paper [2], the PANSS is
a 30 item interval scale ranging from 1-7 which implies
that computations of ratios (e.g. percent changes, like
calculation of XX% PANSS reduction from baseline to
final endpoint) are not appropriate. Ignoring this fact
leads to severe mathematical problems, resulting in an
underestimation of the actual response rate and poten-
tially even to erroneous results. Comparing results with
and without PANSS scale level transformation into a
ratio scale revealed that up to 50% of test decisions may
differ [2]. In a comment on this article [3], Leucht et al.
have cited such erroneous calculation methods as one
reason for low response rates in studies on second gen-
eration antipsychotic drugs.
To avoid incorrect calculations the best solution
would be to subtract the theoretical minimum (which is
30 for the total score), resulting in a score range starting
from zero. Percent changes (PCs) have to be calculated
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verts the PANSS into a ratio scale. Although Leucht et
al. [4,5] have emphasized this necessity previously, the
uncertainty in the psychiatric community remains.
In our previous report we already cited some articles
performing the correction, as well as some others ignor-
ing the pitfall. These examples also included approval
studies of atypical antipsychotics, where a correct calcu-
lation would seem to be particularly important [6].
However, the mentioned articles were neither represen-
tative, nor did they give any answer to the scope of the
problem. So far, knowledge concerning the relative fre-
quency of incorrectly calculated PANSS PCs has been
limited. If papers with erroneous calculations turn out
to be negligible in comparison to similar publications as
a whole, then most researchers seem to be aware of this
pitfall. If not, we need to open a wider debate on this
issue, because results of studies using different methods
for the calculation of PCs can, strictly speaking, not be
compared.
Thus, the aim of this review article is to further inves-
tigate the scope of incorrect PANSS calculations based
on a systematic review of all articles published in the
top ten journals with the highest impact factors in psy-
chiatry, with a focus on the question: Is the PANSS
used correctly?
Methods
All articles in this review were found by a systematic lit-
erature search in the top-ranked psychiatric journals
using Pubmed http://www.pubmed.com based on the
PRISMA statement [7]. The Impact Factor for psychia-
tric journals according to the 2008 Journal Citation
Reports
® Science Edition (Thomson Reuters, 2009) was
used as ranking index. Journals focusing on topics not
related to the PANSS and schizophrenia, such as Mole-
cular Psychiatry or journals specialising in adolescent
psychiatry, were excluded.
Based on these criteria, a predefined Pubmed search
was carried out in the 10 highest-ranked journals enter-
ing the search terms “PANSS” and “response” with no
restrictions regarding date of publication. The search
term “response” was expected to be linked to the calcu-
lation of PCs in the PANSS.
Articles were included if they contained PCs in the
PANSS in any form: Study inclusion criteria as well as
outcome parameters were of interest, as well as continu-
ous PCs and dichotomous response criteria. All articles
containing PCs were included in this review and their
methods of PC calculation were analyzed. The authors
of articles with insufficient method descriptions were
contacted (twice in case of no reply).
A classification was performed independently by two
experienced researchers (MO and FS) into articles with
PC as primary and those with PC as secondary outcome
and into articles using PC as inclusion criteria. In case
of disagreement a third researcher (SM) was consulted
so that all articles could be satisfactorily classified.
Articles grouped according to their PC calculation
method were sub-classified according to their year of
publication, their outcome parameter and their particu-
lar citation number, using nonparametric, rank-based
statistics and corresponding tests.
Results
The ten highest-ranked psychiatric journals according to
their impact factor 2008 included three journals, which
d i dn o tf i to u rs e a r c hc r i t e r i a( M O LP S Y C H I A T R ,J
CHILD PSYCHOL PSYC and J AM ACAD CHILD
PSY). These three journals were therefore replaced by
the three subsequent journals on the impact list (PSY-
CHOL MED, J PSYCHIATR RES, J NEUROL NEURO-
SUR). The search in Pubmed in January 2011 resulted
in 68 publications including both terms, “PANSS” and
“response”. Of all articles, 39 actually used PANSS PC
values ([8-46]) and for 33 articles the method of calcula-
tion could finally be determined. Table 1 shows the
main results in detail.
In summary, in at least 62% of all publications (24 out
of 39) the PANSS PC was calculated without the neces-
sary score correction. The PC calculation method was
rarely specified within the text. It was possible only in
seven articles, to deduce the calculation method without
correspondence with the authors: In two articles with
score correction an explanation of the method was
included and in five articles without correction the cal-
culation method could be identified through an exami-
nation of the presented results.
Most of the articles were from the past few years
(median:2007, range:1995-2010), without any noticeable
difference (p = 0.23) between articles with (median:2008,
range:1995-2010) and without score correction (med-
ian:2006.5, range:1998-2010). The number of citations
ranged from 0 to 447 with a median of 18. As with the
year of publication, there was no significant difference
(p = 0.94) regarding the number of citations in the two
groups. There is a significant negative rank correlation
of -0.70 between citation number and publication year
(p < 0.001).
Regarding the outcome classification of the articles, 33
of the 39 articles could be classified concordantly by
researchers MO and FS, and in six cases a third
researcher (SM) was consulted for the final decision. In
twelve of the 39 publications the primary outcome was
based on PC; in five (42%) of these corrected score
values were used, five (42%) used uncorrected scores,
and in two (17%) the method remained unclear. The
majority of the articles found presented PCs as
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without, and 4 (15%) articles with unknown status.
There was no significant difference between outcome
classification and method (p = 0.09).
Discussion
The influence of the PC calculation method on the
results of double blind placebo controlled trials has
already been described and quantified in detail in our
previous article [2]. There are two main issues, which
need to be considered: (1) Results of studies without
correction cannot be compared to studies with correc-
tion. A 50% response criterion, for example, denotes
two different facts: With corrected scores it corresponds
to a 50% reduction of the measured symptoms, whereas
without correction it corresponds to a 50% reduction of
the score value, which is something very different. (2)
Results are not only incomparable, but could even lead
to different conclusions: While one method might reveal
a significant treatment effect, the other might lead to
the opposite result [2]. In articles with PC as primary
outcome this is particularly problematic, since without
correction even the main conclusion might be erro-
neous. A special issue in this context are approval stu-
dies, which are obliged to follow guidelines like the
EMEA guidelines and therefore regularly include out-
come measures with PCs. For one approval study [6] an
erroneous calculation of the PANSS PC has already
been shown [2].
In combination with the results of the present review
it becomes even more apparent that there is a strong
need for clarification in terms of the PANSS calculation:
Although some authors use corrected scores, in the
majority of cases the correction is not performed. Most
importantly, the non-awareness of this problem is mir-
rored by the fact that only in two articles the score cor-
rection was described in the Methods section. This
suggests that most researchers conducting schizophrenia
trials are not even aware of this pitfall. Considering the
fact that we probably did not identify all relevant articles
in our literature search by focussing on the searching
term of “response” one could assume that there are
even more publications with incorrect PANSS
calculations.
This is even more remarkable keeping in mind that
the papers reviewed were published in high impact
journals. So we can answer the question posed at the
beginning of this article: Yes, the PANSS is used
incorrectly!
What solutions can be made? First of all, it would be
helpful to recalculate studies which have used the
PANSS PC as primary outcome without correction.
For future work with the PANSS a consensus in the
psychiatric research field is needed: Is it enough to cor-
rect the score every time PCs are used or should the
PANSS be rescaled? Leucht et al., in their comment on
our previous paper, prefer the radical solution: The
PANSS items should be rescaled into a scale ranging
from 0 to 6. This would be the most straightforward
solution and could avoid future problems with PCs.
Additionally, renaming the scale as e.g. “PANSS-0” or
“PANSS (ratio version)”, as suggested previously, could
prevent new confusion, which might otherwise arise
with different scale versions.
Conclusions
Again, we emphasize the necessity of further discussion
and a broad consensus on future action in the psychia-
tric community. Until this is achieved we recommend
that, for PANSS PC calculations, all researchers at least
u s et h es c a l ec o r r e c t i o na n di n c l u d eas h o r ts t a t e m e n t
in the description of methods.
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Table 1 Summary of calculation methods in single journals
Abbreviated Journal Title
(Impact Factor 2008)
No. of articles with correction No. of articles
without correction
No. of articles, unknown method
ARCH GEN PSYCHIAT (14.273) 01 [8] 1[9]
AM J PSYCHIAT (10.545) 1[10] 1[11] 0
BIOL PSYCHIAT (8.672) 1[12] 1[13] 0
NEUROPSYCHOPHARMACOL (6.835) 02 [14,15] 1[16]
SCHIZOPHRENIA BULL (6.592) 1[17] 00
BRIT J PSYCHIAT (5.077) 3[18-20] 00
J CLIN PSYCHIAT (5.053) 3[21-23] 11[24-34] 1[35]
PSYCHOL MED (4.718) 01 [36] 2[37,38]
J PSYCHIATR RES (4.679) 07 [39-45] 1[46]
J NEUROL NEUROSUR PS (4.622) 00 0
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